文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles' Heel?

作者信息

Ferreira Leonardo M R, Muller Yannick D

机构信息

Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, United States.

Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States.

出版信息

Front Immunol. 2021 Nov 17;12:766220. doi: 10.3389/fimmu.2021.766220. eCollection 2021.

DOI:10.3389/fimmu.2021.766220
PMID:34868017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8635711/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fd2/8635711/c2ddea7adb69/fimmu-12-766220-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fd2/8635711/c2ddea7adb69/fimmu-12-766220-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fd2/8635711/c2ddea7adb69/fimmu-12-766220-g001.jpg

相似文献

[1]
CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles' Heel?

Front Immunol. 2021-11-17

[2]
The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28.

Front Immunol. 2021

[3]
The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.

Cytotherapy. 2020-4

[4]
Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.

Br J Haematol. 2018-4-10

[5]
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).

BMJ Open. 2020-2-9

[6]
In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.

Mol Ther. 2018-2-2

[7]
Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.

Br J Haematol. 2018-11-8

[8]
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.

Mol Ther. 2018-9-13

[9]
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.

Mol Ther. 2017-7-27

[10]
Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.

Clin Lymphoma Myeloma Leuk. 2021-4

引用本文的文献

[1]
Chimeric anti-HLA antibody receptor engineered human regulatory T cells suppress alloantigen-specific B cells from pre-sensitized transplant recipients.

Front Immunol. 2025-8-15

[2]
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.

Exp Hematol Oncol. 2024-12-4

[3]
Transposon-Based Manufacturing of Human CAR-T Cells.

Methods Mol Biol. 2024

[4]
CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil.

Front Immunol. 2022

[5]
CAR-T cell potency: from structural elements to vector backbone components.

Biomark Res. 2022-9-19

本文引用的文献

[1]
Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.

Front Oncol. 2021-7-26

[2]
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.

Nat Rev Immunol. 2022-2

[3]
The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28.

Front Immunol. 2021

[4]
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies.

Cell. 2020-10-1

[5]
The CD28 Transmembrane Domain Contains an Essential Dimerization Motif.

Front Immunol. 2020

[6]
Tuning the Antigen Density Requirement for CAR T-cell Activity.

Cancer Discov. 2020-5

[7]
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.

Nat Med. 2020-1-20

[8]
Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma.

Mol Ther Oncolytics. 2019-8-28

[9]
Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.

Hematol Oncol. 2019-9-15

[10]
An immunoproteomic approach to characterize the CAR interactome and signalosome.

Sci Signal. 2019-2-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索